The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, ...

The publication of the pricing and reimbursement decision for Pepaxti (melflufen) in the Gazetta Ufficiale removes the last ...

As scientific discovery and technology advance, new opportunities arise and business priorities shift throughout the global ...

Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

The INTERCEPT study is being funded to the tune of €38 million (nearly $40 million) over the next five years and is described ...

It’s always a good sign when a couple of big deals are announced right before the conference, and this year we saw a doozie ...

AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as ...

2025 is going to be a year of great change. At a macro level, political and geopolitical shifts around the world will reshape ...

The healthcare industry experienced a rollercoaster of a year in 2024, with pharmacy benefits undergoing significant shifts.